Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age

Dupilumab, a human monoclonal antibody that blocks interleukin-4 and interleukin-13 pathways, led to histologic remission in a significantly higher percentage of children with eosinophilic esophagitis than placebo.

​   The New England Journal of Medicine: Search Results in Allergy/Immunology